Krishnaswami et al. Researchers at Vanderbilt University found that secretin, a medical treatment for autism spectrum disorders (ASDs) that was popularized in the 1990s, is ineffective in the treatment of ASDs. Evidence from seven randomized controlled trials suggests that secretin does not effectively treat the symptoms of ASDs, which include language and communication impairment, symptom severity, and cognitive and social deficits. Furthermore, no study conducted has found significant improvement in terms of language, cognition, or autistic symptoms when compared with placebo. The Vanderbilt researchers conclude that secretin does not have clear benefit. Additionally, since there is significant evidence of lack of impact in treating ASDs, they believe that further secretin studies should not be conducted.